Highly Potent Active Pharmaceutical Ingredients USA

Highly Potent Active Pharmaceutical Ingredients (HPAPI) USA is organized by SMi Group Ltd and will be held from Oct 21 - 22, 2019 at Sheraton Boston Hotel, Boston, Massachusetts, United States of America.

Who Should Attend:
API specialists, Containment Engineers, Senior Scientists, Head of Scale-up Processings, Occupational Health Officers, Industrial Hygiene Leads, Head of Bioconjugations, Pharmaceutical Company Directors,Preclinical Safety Experts, Biopharmaceutical Developers, Industrial Hygienist, Industrial Hygienist Consultants, Occupational Toxicologists, Occupational Health Experts, Pharamaceutical Company Presidents and Vice Presidents, Head of Toxicology, Process Chemists, Process Research & Develpoment, Head of Technology Transfer

Description:
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers’ safety. 

The event will explore how the latest technologies can benefit HPAPI with artificial intelligence and machine learning to hasten risk assessment and validation. We will also be dedicating much deserved attention on emerging therapies including bispecific antibodies, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? Come and find the answers to these hot topics along with the other unique insights such as continuous manufacturing technologies.

Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Benifits of Attending:
• LEARN how to rationally categorise your HPAPI project into a containment banding and implement containment solutions to mitigate the occupational health risks
• GRASP the current landscape of HPAPI ADCs and other emerging biologics-based therapies including hormones, oncolytic viral complexes, bispecific antibodies and oligonucleotide
• DISCOVER the emerging HPAPI manufacturing technologies to reduce powder exposure with the possibility of continuous manufacturing for HPAPI
• UNDERSTAND the steps involved to evolve a containment environment to match that of the its scale of production and value of this practice

Additional details will be posted as soon as they are available.